ReviewCurrent urology reports2018
Contemporary Review of Peyronie's Disease Treatment.
Review in Current urology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: An Evidence-Based Analysis.Frontiers in medicine · 2022Pooled it
- Impact ofInternational journal of molecular sciences · 2026Article
- Article
- Novel grafting technique using femoral subcutaneous tissue in the surgical management of Peyronie's disease: A case report.International journal of surgery case reports · 2025Article
- A review of Peyronie's disease insurance coverage.Sexual medicine · 2024Article
- Measurement of Oxidative Stress Index (OSI) in Penile Corpora Cavernosa and Peripheral Blood of Peyronie's Disease Patients: A Report of 49 Cases.Metabolites · 2024Article
- Molecular Mechanisms and Risk Factors Related to the Pathogenesis of Peyronie's Disease.International journal of molecular sciences · 2023Review
- Use of penile shear wave elastosonography for the diagnosis of Peyronie's Disease: a prospective case-control study.Basic and clinical andrology · 2022Article
- ESSM Position Statement on Surgical Treatment of Peyronie's Disease.Sexual medicine · 2022Review
- The efficacy and safety of intralesional injection of collagenaseFrontiers in pharmacology · 2022Review
- Causal contributors to tissue stiffness and clinical relevance in urology.Communications biology · 2021Review
- The Natural History of Peyronie's Disease.The world journal of men's health · 2021Review
- Outcome analysis of patients with Peyronie's disease who elect for vacuum erection device therapy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- Negative Self-Perception and Self-Attitude of Sexuality Is a Risk Factor for Patient Dissatisfaction Following Penile Surgery with Small Intestinal Submucosa Grafting for the Treatment of Severe Peyronie's Disease.Journal of clinical medicine · 2019Article
- Editorial Comment on 'Limited success with Clostridium Collagenase Histolyticum following FDA approval for the treatment of Peyronie's disease'.International journal of impotence research · 2019Article
- Effects of plication procedures in special cases of Peyronie's disease: a single-center retrospective study of 72 patients.Asian journal of andrologyArticle
- Effects of patients' understanding and choice of surgical types on postoperative outcomes of Peyronie's disease: a single-center retrospective study of 108 patients.Asian journal of andrologyArticle
- The use of penile traction therapy in the management of Peyronie's disease: current evidence and future prospects.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze the literature on the current treatment options for Peyronie's disease (PD). RECENT
findingsIntracavernosal injection therapy using collagenase clostridium histolyticum (CCH) has been widely adopted since its FDA approval in 2013. Based on the current evidence, it appears to be moderately efficacious for men with mild curvatures. Although a recent study has shown similar outcomes using a modified protocol requiring fewer injections, CCH remains an expensive medication. Surgery provides the most definitive treatment. The most common adverse effect following surgery is perceived loss of length. Length restoration procedures have recently been developed to address this with promising results reported in small series. There are a variety of medical treatment options for PD, with CCH getting the most attention for being the first drug to be FDA approved for PD treatment. It is the authors' opinion that the non-surgical therapy most likely to provide meaningful results is combination therapy utilizing oral, intralesional, and external traction therapy. Surgery remains the gold standard for definitive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.